Sera Prognostics, Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $42,000 (+162.5% year over year) and diluted EPS of -$0.16. It usually reports 35–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 12, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Friday. Based on how many days after a quarter ends the company has reported recently. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
0
+162.5%
|
-8
-3.1%
|
-0.16
+0.0%
|
|
Aug 12, 2026
43 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
+76.5%
|
-9
-13.6%
|
-0.18
-12.5%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
-63.2%
|
-8
-2.6%
|
-0.17
+15.0%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
-44.8%
|
-8
+1.3%
|
-0.16
+33.3%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
0
-29.2%
|
-8
+3.1%
|
-0.16
+36.0%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
0
|
-8
-1.1%
|
-0.20
+20.0%
|
|
Jan 31, 2025
31 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
0
-41.5%
|
-9
-8.3%
|
-0.25
-0.2%
|
|
Nov 6, 2024
37 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- SERA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1534969
- Former names
- SERA PROGNOSTICS, INC. (until Nov 4, 2026)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.